BridgeBio to present Phase 3 infigratinib achondroplasia data at ICCBH

BridgeBio will share primary Phase 3 PROPEL 3 results for oral infigratinib in children with achondroplasia at ICCBH 2026 in Montreal.

The Biotech Times Editorial Team By The Biotech Times Editorial Team
A brightly lit medical examination room features a white medical imaging machine with a patient bed, dual computer monitors on a wooden counter, and a potted plant next to a large window.

BridgeBio Pharma will present primary results from PROPEL 3, its global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, as a late-breaking oral presentation at the International Congress of Children's Bone Health (ICCBH 2026) in Montreal, Canada. The presentation is scheduled for 28 June at 3:45 pm EDT and will be delivered by Ravi Savarirayan, global lead investigator for PROPEL 3 and a researcher at the Murdoch Children's Research Institute in Melbourne, Australia.

The release describes the findings as "additional positive data," though BridgeBio has not yet disclosed the primary efficacy metrics, hazard ratios or safety profile in the pre-congress announcement. Delegates attending the session will be among the first to see the full dataset.

What BridgeBio is presenting

Beyond the headline PROPEL 3 readout, BridgeBio will present a broad portfolio of achondroplasia and skeletal dysplasia data across the four-day congress. An oral presentation on 29 June will cover health-related quality-of-life findings from the observational PROPEL study. Four posters will address early intervention, including the design of PROPEL Infant and Toddler, a Phase 2/2b study evaluating infigratinib in children under three years old; observational data on hypochondroplasia from the ACCEL study; patient-reported outcome measures for hypochondroplasia; and the MyAchonJourney online education platform. A separate poster will present baseline disease burden and quality-of-life data from CLARIFY, BridgeBio's monitoring study of autosomal dominant hypocalcemia type 1 and type 2.

The breadth of the programme signals BridgeBio's intent to position itself as the leading commercial and scientific presence in skeletal dysplasias, a rare-disease category that has attracted growing industry attention in recent years.

Market context and competitive landscape

Achondroplasia, caused by gain-of-function mutations in the FGFR3 gene, has historically had no approved pharmacological treatment. That changed in 2021 when Voxzogo (vosoritide), a C-type natriuretic peptide analogue developed by BioMarin Pharmaceutical, received approvals from both the FDA and EMA for children with open growth plates. BridgeBio is pursuing a differentiated mechanism: infigratinib is an oral, selective FGFR inhibitor, and its small-molecule, once-daily profile could offer a meaningful convenience advantage over vosoritide's daily subcutaneous injection.

A positive PROPEL 3 readout would position BridgeBio to file for regulatory approval in the US and Europe, and the company has previously flagged a potential NDA submission as a near-term milestone. The FDA has granted infigratinib Breakthrough Therapy designation for achondroplasia, which would provide more intensive guidance and an expedited review pathway. Investors and patient advocates will be watching the conference presentation closely for annualised growth velocity data and the safety profile across age cohorts, both of which will be central to any regulatory submission and eventual label negotiations.

Sector

Topic

Geography